EASL Highlights and Next Steps
• Nucs are effective, but do not eliminate residual HBV DNA and HBV RNA
• Combination of 731+ Nuc demonstrated potential to eliminate residual HBV DNA
• Core Inhibitors have the potential to be the backbone of future HBV regimens
– We believe that elimination of residual viremia will likely be a critical milestone required to increase
rates of cure
• 2158 currently in dose finding Phase 1b study and Phase 2a studies expected to follow
immediately
• 3733 expected to initiate Phase 1a study in early 2020
• Initiating discussions with global regulatory bodies regarding design of next studies and
pathways to approval for 731 + Nuc combination 作者: newchinabok 时间: 2019-4-15 21:57
Initiating discussions with global regulatory bodies regarding design of next studies and
pathways to approval for 731 + Nuc combination与全球监管机构就731+Nuc组合的下一项研究和批准途径的设计展开讨论。(个人认为fda快速通道上市)
Initiating discussions with global regulatory bodies regarding design of next studies and
pathways to approval for 731 + Nuc combination与全球监管机构就731+Nuc组合的下一项研究和批准途径的设计展开讨论。